Argentina Detects New COVID-19 Variant PJ.2.1 With Higher Cell Affinity; WHO Rates Risk Low

Argentinian researchers have identified three cases of the PJ.2.1 SARS-CoV-2 variant, a JN.1 descendant carrying 25 genetic mutations that shows increased binding affinity to the human ACE2 receptor, El Intransigente reported, according to Elintransigente.

The detection by the National University of La Plata (UNLP) involved two infants aged one and two months and a 58-year-old adult, all hospitalized.

Virologist Paola Resende explained the lineage possesses genomic mutations granting higher affinity for cellular receptors, increasing transmissibility, though the World Health Organization (WHO) assessed the additional global public health risk as low in a November 19 evaluation, noting limited confidence in that valuation due to insufficient comparative clinical data.

Lab Data Shows Tighter ACE2 Binding

  • Transmission: Lab data shows the variant binds more tightly to the ACE2 receptor—the doorway the virus uses to enter human cells—but this has not yet been proven to cause faster spread between people.
  • Severity: Current hospital data suggests a rise in mild pediatric cases and potentially greater severity in adults, though no unique symptom profile distinguishes PJ.2.1 from other Omicron sublineages.
  • Protection: Antibodies from vaccines updated for recent variants (LP.8.1 and XFG) neutralized PJ.2.1 in lab tests, but real-world effectiveness against infection or severe disease remains unquantified.

PJ.2.1 Shows Enhanced ACE2 Receptor Binding

PJ.2.1 descends from JN.1, a major Omicron branch, accumulating 25 genetic modifications relative to its immediate predecessor. Researchers at the UNLP Public Health Laboratory, Genomic and Molecular Area, Faculty of Exact Sciences, sequenced the three local cases. Laboratory assays demonstrated that PJ.2.1 spike protein binds with greater capacity to the angiotensin-converting enzyme 2 (ACE2) receptor compared to some contemporary variants.

Since ACE2 is the primary entry point for SARS-CoV-2 into human respiratory epithelium, this enhanced affinity provides a plausible biological mechanism for increased infectivity, though Resende cautioned that receptor binding alone does not confirm higher interpersonal transmission.

WHO Risk Assessment and Immunological Data

The WHO classified PJ.2.1 as a Variant Under Monitoring (VUM) amid growth in multiple regions, including the United States, Canada, and Brazil. In its November 19 risk evaluation, the agency stated the additional global public health risk posed by PJ.2.1 is low, while explicitly flagging low confidence in that assessment.

Critical evidence gaps remain: no comparative clinical data yet exists to determine if PJ.2.1 alters disease severity, hospitalization rates, or mortality. Neutralization assays using sera from individuals vaccinated with formulas adapted to LP.8.1 and XFG showed retained neutralizing capacity against PJ.2.1, yet the WHO emphasized these laboratory results cannot alone establish clinical vaccine effectiveness against infection or severe outcomes.

“Posee mutaciones en su genoma que le confieren mayor afinidad con los receptores de nuestras células, lo que aumenta su transmisibilidad,”

Paola Resende, virologist, UNLP Public Health Laboratory, told El Intransigente

Pediatric and Adult Clinical Picture in Argentina

Roberto Debbag, president of the Latin American Society of Vaccinology, stated cases "definitively are rising," noting admissions of children under six months with COVID-19 and respiratory syncytial virus (RSV) coinfection.

Vaccination Gaps: Pregnancy and National Formulations

RSV vaccination in pregnant women reached approximately 80%, yet SARS-CoV-2 vaccination coverage in the same group remains below 10%. Debbag emphasized that pregnant individuals can receive COVID-19 vaccination in any trimester.

Argentina currently deploys an mRNA vaccine free of charge at public centers and ARVAC, a nationally developed recombinant protein vaccine, available in pharmacies. The immunogenicity of these specific formulations against PJ.2.1 has not been publicly detailed, though the WHO’s neutralization data on updated LP.8.1 and XFG formulas offers indirect reassurance.

Regional Response and Surveillance Gaps

In Formosa province, health authorities reinstated swabbing and PCR testing following a sharp case increase during the last week of November. The return of active surveillance shows how uneven genomic monitoring is across the country; UNLP found only three sequenced cases, too few to gauge true community prevalence.

The WHO’s “limited confidence” rating reflects this global surveillance deficit—without expanded sequencing, shifts in severity or immune escape may go undetected until hospitalizations rise.

Symptoms Indistinguishable from Other Omicron Subvariants

No specific contraindications exist for PJ.2.1 exposure beyond standard SARS-CoV-2 precautions.

The National University of La Plata, where the UNLP Public Health Laboratory conducted the sequencing, began operations on April 18, 1897, as the Universidad Provincial de La Plata and was nationalized in 1905 under Joaquín V. González. Today it enrolls over 90,000 regular students across 17 departments and 106 degrees.

Its research infrastructure includes the La Plata Museum of Natural Sciences, which holds one of South America’s most important paleontological and anthropological collections, and the Astronomical Observatory, integrated during the university’s nationalization.

Symptom profiles for PJ.2.1—fever, cough, sore throat, rhinorrhea—remain indistinguishable from other Omicron subvariants; diagnosis requires PCR or genomic sequencing, not clinical judgment alone.

References

  • World Health Organization. Weekly Epidemiological Update on COVID-19 (19 November 2026).
  • Universidad Nacional de La Plata. UNLP Public Health Laboratory Genomic Surveillance Report.
  • Latin American Society of Vaccinology (SLV). Statements on COVID-19 and RSV Coinfection in Pediatrics.
  • Ricardo Gutiérrez Children’s Hospital. Respiratory Virus Surveillance Bulletins, November 2026.
  • Ministry of Health, Argentina. National COVID-19 Vaccination Campaign: mRNA and ARVAC Deployment.
Photo of author

Health Desk

Health Desk at Archyde.

CPSC Warns of Drowning Risk From Qing Song Snorkel Masks Sold on Amazon, TikTok

Slavs and Tatars Opens First Dutch Solo Show “Mouthfool” at Rotterdam’s Fenix Museum